doi: 10.3389/fphar.2022.1026182 Received 23 August 2022 Accepted 23 November 2022 Published 14 December 2022 Volume 13 - 2022 Edited by Junmin Zhang, Lanzhou University, China Reviewed by Yurong Lai, Gilead, United States Mei-Hua Qu, Weifang Second Peoples Hospital, China Updates Copyright 2022 He, Feng, Guo, Zhou, Li, Zhang, Zhang, Wang, Wang, Hao, Zhang, Gao, Gu, Zhang, Li and Li
Novo Nordisk continues to emphasize safe administration, dose titration, and long-term monitoring to help patients achieve meaningful, sustained outcomes
Inject during the fasting window, not during the eating window
Additionally, as improved odds for oral increase the chances that supply will be able to meet demand and these second order effects will materialize on a faster time frame, making sell side estimates for penetration look very low
10.3390/ph14100982 21 BurbullaL